Anumana was founded in 2021 as the culmination of a joint effort between the Mayo Clinic and nference, an early entrant to the field of machine learning for cardiology-focused clinical solutions. By leveraging large stores of deidentified data that span full patient journeys from physician notes to medications and imaging files, Anumana develops cardiac AI-based solutions that can glean pertinent disease information from electrocardiogram (ECG)waveforms. The company’s first FDA-cleared cardiac ECG-AI algorithm detects low ejection fraction (LEF), and two additional algorithms for pulmonary hypertension and cardiac amyloidosis are under review.
Anumana Makes Educated Inferences in Heart Failure
Related Articles
Anumana Appoints Maulik Nanavaty as CEO
Anumana Appoints Maulik Nanavaty as CEOCAMBRIDGE, Mass. – October 19, 2023 – Anumana, Inc., a leading AI-driven health technology company and portfolio company of nference, today announced that Maulik Nanavaty…{post_date: F d, Y}
Cardiology’s AI Moment: Anumana’s Top Insights from ACC.25
#TeamAnumana wrapped up three incredible days of exploring cardiovascular science in the Windy City at the American College of Cardiology’s Annual Scientific Session. ACC.25 brought together thousands of cardiologists, investigators,…{post_date: F d, Y}
Anumana’s ECG-AI® Algorithms Honored with 2024 MedTech Breakthrough Award for “Best New Technology Solution-Cardiology”
Anumana’s innovative AI algorithms recognized for their transformative potential in cardiology - the first of which is now commercially available{post_date: F d, Y}
Anumana wins FDA breakthrough nod for AI algorithm that detects pulmonary hypertension
Mass Device: Anumana announced today that it received FDA breakthrough device designation for its pulmonary hypertension (PH) early detection algorithm. Cambridge, Massachusetts-based Anumana, formed by Mayo Clinic and nference and launched in…{post_date: F d, Y}